Literature DB >> 11469418

Endothelin system in human persistent and paroxysmal atrial fibrillation.

B J Brundel1, I C Van Gelder, A E Tuinenburg, M Wietses, D J Van Veldhuisen, W H Van Gilst, H J Crijns, R H Henning.   

Abstract

INTRODUCTION: Activation of the endothelin system is an important compensatory mechanism that is activated during left ventricular dysfunction. Whether this system plays a role at the atrial level during atrial fibrillation (AF) has not been examined in detail. The purpose of this study was to investigate mRNA and protein expression levels of the endothelin system in AF patients with and without concomitant underlying valve disease. METHODS AND
RESULTS: Right atrial appendages of 36 patients with either paroxysmal or persistent AF were compared with 36 controls in sinus rhythm. The mRNA amounts of pro-endothelin-1 (pro-ET-1), endothelin receptor A (ET-A), and endothelin receptor B (ET-B) were studied by semiquantitative polymerase chain reaction. Protein amounts of the receptors were investigated by slot-blot analysis. mRNA amounts of pro-ET-1 were increased (+40%; P = 0.002) only in AF patients with underlying valve disease. ET-A and ET-B receptor protein amounts were significantly reduced in patients with paroxysmal AF (-39% and -47%, respectively) and persistent AF with underlying valve disease (-28% and -30%, respectively) and in persistent AF without valve disease (-20% and -40%, respectively). ET-A mRNA expression was unaltered in paroxysmal and persistent AF, whereas ET-B mRNA was reduced by 30% in persistent AF with (P < 0.001) or without (P = 0.04) valve disease, but unchanged in paroxysmal AF.
CONCLUSION: Substantial changes in gene expression of the endothelin system were observed in human atria during AF, especially in the presence of underlying valve disease. Alterations in endothelin expression associated with AF could play a role in the pathophysiology of AF and the progression of underlying heart disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469418     DOI: 10.1046/j.1540-8167.2001.00737.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  11 in total

1.  Big endothelin-1 as a predictor of atrial fibrillation recurrence after primary ablation only in patients with paroxysmal atrial fibrillation.

Authors:  H Wang; J Liu; P Fang; S Lei; X Li; Y Hou; S Zhang
Journal:  Herz       Date:  2012-06-06       Impact factor: 1.443

2.  Endothelin system and atrial fibrillation post-cardiac surgery.

Authors:  Theofilos M Kolettis; Zenon S Kyriakides; Eleni Zygalaki; Stamatis Kyrzopoulos; Loukas Kaklamanis; Nikolaos Nikolaou; Evi S Lianidou; Dimitrios Th Kremastinos
Journal:  J Interv Card Electrophysiol       Date:  2008-02-09       Impact factor: 1.900

Review 3.  Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation.

Authors:  Stanley Nattel; Dobromir Dobrev
Journal:  Nat Rev Cardiol       Date:  2016-08-04       Impact factor: 32.419

4.  [Molecular biology of the heart atrium. New insights into the pathophysiology of atrial fibrillation as well as its clinical implications].

Authors:  A Goette; U Lendeckel; H U Klein
Journal:  Z Kardiol       Date:  2004-11

5.  Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease.

Authors:  Fadia Mayyas; Mark Niebauer; Andrew Zurick; John Barnard; A Marc Gillinov; Mina K Chung; David R Van Wagoner
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-05-21

6.  Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease.

Authors:  A Boldt; U Wetzel; J Lauschke; J Weigl; J Gummert; G Hindricks; H Kottkamp; S Dhein
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

Review 7.  Rate Control Strategy Elevated To Primary Treatment For Atrial Fibrillation: Has The Last Word Already Been Spoken?

Authors:  Osmar Antonio Centurión; Akihiko Shimizu
Journal:  J Atr Fibrillation       Date:  2014-12-31

8.  Multiple biomarkers and atrial fibrillation in the general population.

Authors:  Renate B Schnabel; Philipp S Wild; Sandra Wilde; Francisco M Ojeda; Andreas Schulz; Tanja Zeller; Christoph R Sinning; Jan Kunde; Karl J Lackner; Thomas Munzel; Stefan Blankenberg
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

9.  Associations of big endothelin-1 and C-reactive protein in atrial fibrillation.

Authors:  Li-Hui Zheng; Wei Sun; Yan Yao; Bing-Bo Hou; Yu Qiao; Shu Zhang
Journal:  J Geriatr Cardiol       Date:  2016-07       Impact factor: 3.327

10.  Association between big endothelin-1 and CHADS2/CHA2DS2-VASc scores in non-valvular atrial fibrillation.

Authors:  Li-Hui Zheng; Shang-Yu Liu; Feng Hu; Er-Peng Liang; Ling-Min Wu; Hong-Lei Wang; Ammar M Killu; Yan Yao
Journal:  J Geriatr Cardiol       Date:  2019-11       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.